153
Participants
Start Date
May 31, 2006
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2010
CP-4055
CP-4055 Continuous IV infusion
CP-4055
CP4055 2 and 4 hour IV infusion
Mew York Medical College, Division of Oncology, Valhalla
University Hospital Benjamin Franklin Med.Clinic III, Berlin
Institut Paoli-Calmettes, Marseille
Duke University Medical Center (DUMC), Durham
Institute of Hematology & Medical Oncology L and A Serágnoli University of Bologna, Bologna
Cleveland Clinic Taussig Cancer Center, Cleveland
Westfälische Wilhelms-Universität Münster Medizinische Klinik und Polikinik Innere Medizin A, Münster
Department of Internal Medicine Klinikum der Johann Wolfgang Goethe-Universität Medizinische Klinik II, Frankfurt am Main
Centre Hospitalier Universitaire, CHU de Lyon, Service d'Hematologie Clinique, Lyon
MD Anderson Cancer Center, Houston
Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd., San Antonio
Hematology Service, Hôpital Beaujon and Hôpital Avicenne, Bobigny
Centre Hospitalier Universitaire CHU de Toulouse, Hopital Purpan, Toulouse
Universitá degli Studi di Roma Ematologia- Policlinico Tor Vergata, Rome
Department of Hematology, Ullevål University Hospital, University of Oslo, Oslo
Christie Hospital, Manchester
Lead Sponsor
Clavis Pharma
INDUSTRY